Apr. 21 at 12:57 AM
This is a dangerous time for
$SNDX investors. In 8 days
$INCY reports Q126 Niktimvo sales. 7 days later SNDX reports Revuforj sales.
Absent wins in the clinic (rare in cancer research), its our experience actual sales v analyst expectations are the most meaningful drivers of change in valuations for comm'l-stage oncology focused bios like SNDX.
The historical evidence is overwhelming shareholder value of comm'l-stage oncology focused bios like SNDX is maximized via M&A exit w/in 2 years of FDA approval. 90% of SNDX peers not sold within 2 years are sold @ meaningful losses. We've posted actuals back to 1/1/13 time & again
Read our 3/28/26 post where we show SNDX's CEO only makes
$81MM if SNDX is acquired for
$36/sh. He makes
$110MM @
$44/sh. The decision on what's best must be stressful beyond belief
While the XBI has surged 7% higher over the last 12 days to 5-year highs, SNDX has traded down 5% (graph). SNDX has executed flawlessly to date. Fingers crossed on Q1...
$KURA ?
$XBI $IBB